VIP — Vasoactive Intestinal Peptide
A 28-amino-acid neuropeptide at the intersection of vasodilation, immunomodulation, and neuroprotection
Vasoactive Intestinal Peptide (VIP) is an endogenous 28-amino-acid neuropeptide that was isolated from the small intestine in 1970 and belongs to the secretin-glucagon superfamily. Its effects are remarkably broad: it regulates vasodilation, modulates the immune system, protects neuronal cells, and influences glucose and lipid metabolism. In the context of longevity and anti-aging, VIP is increasingly coming into focus because it may dampen age-associated inflammatory processes and reinforce cellular protective mechanisms.
Summary
- VIP is an endogenous 28-amino-acid peptide from the secretin-glucagon superfamily with three main receptors: VPAC1, VPAC2, and PAC1.
- It has vasodilatory, immunomodulatory (Th2 shift), neuroprotective, and anti-inflammatory effects.
- Clinical and preclinical data show therapeutic potential in type 2 diabetes mellitus, neurodegenerative diseases, osteoarthritis, Sjögren's syndrome, and viral infections.
- The short plasma half-life (approx. 2 minutes) requires nanoparticle formulations or stable analogs for therapeutic application.
- VIP-based therapies are not currently approved for longevity applications; the evidence is predominantly preclinical.
Key Insight
VIP possesses a unique pleiotropic action profile that simultaneously addresses multiple aging-relevant mechanisms: chronic inflammation ("inflammaging"), endothelial dysfunction, and neuronal degeneration. The pharmacokinetic limitation due to an extremely short half-life is the main obstacle to clinical translation. Nanoparticle-based delivery systems and stable VIP analogs are the most promising strategies to harness the therapeutic potential of VIP for longevity applications.
Mechanism of Action
VIP binds to three G-protein-coupled receptors (GPCRs): VPAC1, VPAC2, and PAC1 (Pituitary Adenylate Cyclase-Activating Polypeptide Receptor 1). Receptor binding predominantly activates the cAMP/PKA signaling pathway but also leads to activation of cGMP, phospholipase C, and MAPK cascades. This pleiotropic signaling explains the extraordinarily broad action profile of the peptide.
In the cardiovascular system, VIP produces potent vasodilation through nitric oxide (NO)-dependent and -independent mechanisms. It relaxes vascular smooth muscle, lowers blood pressure, and improves endothelial function. These properties are particularly relevant in the context of aging, as endothelial dysfunction is a central driver of cardiovascular morbidity in old age.
In terms of immunomodulation, VIP acts through a shift of the T-helper response from Th1/Th17 toward Th2, suppression of pro-inflammatory cytokines (TNF-α, IL-6, IL-12), and induction of anti-inflammatory mediators (IL-10). This immunomodulation strikes at the core of the "inflammaging" concept — the chronic, low-grade inflammation that accompanies aging and promotes numerous age-related diseases.
In the nervous system, VIP exerts neuroprotective effects through reduction of oxidative stress, promotion of neuronal survival signals, and modulation of glial cell activity. It reduces apoptosis in neurons and protects against excitotoxicity. Additionally, VIP regulates circadian rhythms through its role as a neuromodulator in the suprachiasmatic nucleus (SCN) — the body's central clock generator, whose function declines with age.
In metabolism, VIP stimulates insulin secretion from beta cells, promotes glycogenolysis, and regulates glucose and lipid metabolism. Activation of the VPAC2 receptor in pancreatic beta cells is of particular importance for glucose homeostasis and makes VIP an interesting target in the context of type 2 diabetes mellitus and metabolic syndrome — both conditions associated with premature aging.
Clinical Evidence
The clinical evidence for VIP is heterogeneous and spans a spectrum from basic pharmacological studies to preclinical disease models. The following overview summarizes the key PubMed-verified studies:
- Type 2 diabetes mellitus: A review in Frontiers in Endocrinology (2022, PMID 36204104) analyzes the therapeutic potential of VIP and its receptor VPAC2 in type 2 diabetes. VPAC2 activation in beta cells promotes glucose-dependent insulin secretion without causing hypoglycemia — an advantage over conventional sulfonylureas.
- Therapeutic applications: In Current Opinion in Endocrinology, Diabetes and Obesity (2021, PMID 33481421), the clinical translation of VIP-based therapies is systematically discussed. The authors emphasize that stable VIP analogs and targeted delivery systems are required to overcome the short biological half-life.
- Neurological diseases: A review in CNS & Neurological Disorders - Drug Targets (2010, PMID 20632962) summarizes the neuroprotective potential of VIP in neurodegenerative diseases. It reduces neuroinflammatory processes, protects dopaminergic neurons, and shows preclinical efficacy in models of Parkinson's disease and Alzheimer's dementia.
- Osteoarthritis: A study in Journal of Biomedical Science (2016, PMID 27553659) investigates the role of VIP in osteoarthritis. It inhibits pro-inflammatory cytokines in synovial cells and reduces cartilage degradation in the preclinical model. The anti-inflammatory effect is predominantly supported by preclinical evidence.
- Sjögren's syndrome: A study in Immunology & Inflammation Diseases (2023, PMID 37506142) shows that VIP exerts therapeutic effects through regulation of PTEN in a Sjögren's model. This underscores the immunomodulatory potential in autoimmune diseases.
- Nanoparticle delivery: In Advances in Protein Chemistry and Structural Biology (2015, PMID 25819279), VIP nanoparticles for diagnostic and controlled drug delivery applications are described. These formulations increase bioavailability and enable targeted delivery.
- Antiviral therapy: A paper in Sheng Li Xue Bao (2022, PMID 35770640) identifies VIP as a potential target for antiviral therapies, as it modulates inflammatory cytokine storms that are pathogenically active in viral infections.
- Structure-activity relationship: A pharmacological study in Naunyn-Schmiedeberg's Archives of Pharmacology (2008, PMID 18172612) describes potent VIP agonists and antagonists and provides the molecular basis for the development of stable VIP derivatives with longer half-lives.
Comparison with Related Peptides
| Peptide | Amino acids | Main effect | Half-life | Evidence level |
|---|---|---|---|---|
| VIP | 28 | Vasodilation, immunomodulation, neuroprotection | ~2 min | Preclinical, individual clinical trials |
| PACAP | 27/38 | Neuroprotection, neurotrophic | <5 min | Preclinical |
| Secretin | 27 | Pancreatic secretion, gastrointestinal | ~3 min | Clinically established (diagnostics) |
| Glucagon | 29 | Blood sugar regulation, glycogenolysis | ~3–6 min | Clinically established |
| GLP-1 | 31 | Incretin, insulin secretion, neuroprotection | ~2 min (native) | Clinically established (analogs) |
Side Effects & Safety
The short plasma half-life of VIP (approx. 2 minutes) limits systemic side effects during endogenous release. For therapeutic application — particularly as a stable analog or in nanoparticle formulation — the following aspects should be noted:
- Cardiovascular: Hypotension and tachycardia due to vasodilation, particularly with intravenous administration.
- Gastrointestinal: Diarrhea, flushing, abdominal pain (VIP was originally described as an intestinal secretion-stimulating peptide).
- Metabolic: Possible effects on glucose homeostasis, risk of hyperglycemia at high dosages.
- Immunological: Long-term immunomodulation may affect defense against infections and malignant cells. Careful monitoring of immune function is required with chronic use.
Contraindications: Severe hypotension, advanced heart failure, acute infections. Insufficient data are available for use during pregnancy and lactation. Long-term safety data for VIP analogs are lacking.
Practical Implications
For the field of longevity and anti-aging, VIP is currently a purely experimental agent. The evidence for longevity applications is predominantly preclinical. The following aspects are relevant for practice:
- Not for self-administration: VIP is not approved in any country for longevity or anti-aging applications. All clinical applications are in the experimental stage.
- Nanoparticle strategies: The most promising route for future therapeutic applications is nanoparticle-based delivery systems that enable targeted delivery and controlled release.
- VPAC2 agonists: Selective VPAC2 agonists could represent a safer alternative to native VIP, as they isolate the metabolic effects without fully expressing the vasodilatory side effects.
- Biomarker monitoring: If VIP-based therapies are used in clinical trials, endothelial function (flow-mediated dilation), immune markers (cytokine profile), and glucose homeostasis should be monitored.
- Combination potential: VIP could meaningfully be combined with other peptides that address complementary mechanisms (e.g., DSIP for sleep, Thymosin alpha-1 for immunomodulation). However, evidence for such combinations is lacking.
Regulatory Notice
IMPORTANT: VIP is not approved as a medicinal product for longevity or anti-aging applications in the EU, the USA, or other regions. It is not registered as a dietary supplement, cosmetic, or medical device for this purpose. Preparations containing VIP that are sold online without a prescription are unregulated, potentially contaminated, and may pose health risks. Possession of VIP in injectable form may be illegal in many countries. Any use should take place exclusively within the framework of clinical trials under medical supervision.
Outlook
The future of VIP in longevity medicine depends on two developments: First, the availability of stable VIP analogs with longer half-lives and more selective receptor profiles; second, the development of nanoparticle delivery systems that enable targeted delivery and controlled release. Initial clinical trials with VIP analogs for inflammation and metabolic diseases are expected.
A particularly promising strategy is the development of selective VPAC2 agonists for type 2 diabetes mellitus that isolate the metabolic benefit of VIP without the vasodilatory side effects. Such analogs could also be relevant for longevity applications, as metabolic health is a central factor for healthy aging.
Conclusion
VIP is one of the most fascinating peptides in human physiology with pleiotropic effects on the vascular system, immune system, nervous system, and metabolism. In the context of longevity and anti-aging, it addresses several core mechanisms of aging simultaneously: inflammaging, endothelial dysfunction, and neuronal degeneration. However, clinical translation is limited by the short plasma half-life and broad receptor binding. Stable analogs and nanoparticle formulations are the most promising strategies to harness the therapeutic potential of VIP. Until such formulations become clinically available, VIP remains an experimental agent with substantial but not yet realized potential for longevity medicine.
Protocol & Dosage
The following dosages are based on community protocols. They do not constitute medical advice. VIP is not FDA-approved and is used for research purposes. Note: There is no established clinical dosage for VIP — the following information is community-based.
📋 Standard Protocol (Community-based)
- Dose: 100–300 mcg subcutaneous
- Frequency: 1–2× daily
- Timing: Flexible — no strict fasting requirement
- Route of administration: Subcutaneous
- Cycle: 4–8 weeks, followed by a break
Reconstitution
5 mg vial + 2 mL bacteriostatic water = 2.5 mg/mL concentration. On a U-100 insulin syringe: 100 mcg = 4 units, 200 mcg = 8 units, 300 mcg = 12 units.
Special Notes
No established clinical dosage: VIP has a very short plasma half-life (approx. 1–2 minutes in vivo). The dosages listed above are derived from community experience, not from clinical trials. The broad receptor binding (VPAC1, VPAC2) can lead to significant vasodilatory side effects (flushing, blood pressure drop, tachycardia).
Caution with hypotension: VIP is a potent vasodilator. If you have low blood pressure or a tendency toward hypotension, VIP should not be used. Monitor blood pressure before and during the cycle.
Duration: 4–8 weeks per cycle. Longer periods of use should be accompanied by medical supervision and lab monitoring.
⚠️ Regulatory Notice
This protocol is based on community observations, as no established clinical dosage exists for VIP. It is not validated by FDA-approved clinical trials. VIP is not approved for human use. Consult a qualified physician before use.
Sources
- PMID 36204104 — Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes. Front Endocrinol, 2022.
- PMID 33481421 — Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): therapeutic applications. Curr Opin Endocrinol Diabetes Obes, 2021.
- PMID 20632962 — Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological diseases. CNS Neurol Disord Drug Targets, 2010.
- PMID 27553659 — Role of vasoactive intestinal peptide in osteoarthritis. J Biomed Sci, 2016.
- PMID 37506142 — Vasoactive intestinal peptide exerts therapeutic action by regulating PTEN in a model of Sjögren's syndrome. Immun Inflamm Dis, 2023.
- PMID 25819279 — Vasoactive Intestinal Peptide (VIP) Nanoparticles for Diagnostics and for Controlled and Targeted Drug Delivery. Adv Protein Chem Struct Biol, 2015.
- PMID 35770640 — Vasoactive intestinal peptide: a potential target for antiviral therapy. Sheng Li Xue Bao, 2022.
- PMID 18172612 — Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and antagonists. Naunyn Schmiedebergs Arch Pharmacol, 2008.